Impact of adjuvant chemotherapy on frailty, cognitive function, and quality of life in older patients with breast cancer_CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Authors：

WU Yunhao ,  CHEN Jie

Department of Breast Surgery, West China Hospital of Sichuan University, Chengdu 610041, P. R. China;

Corresponding author：

CHEN Jie, Email: chenjiedoctor@126.com

Keywords：

breast cancer; older patient; adjuvant chemotherapy; frailty; cognitive function; quality of life; review

DOI：

10.7507/1007-9424.202001071

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To summarize the research progress on the impact of postoperative adjuvant chemotherapy on frailty, cognitive function, and quality of life in older patients with breast cancer.Method Collected literatures about the impact of postoperative adjuvant chemotherapy on frailty, cognitive function, and quality of life in older patients with breast cancer to make an review.Results Elderly breast cancer patients were likely to benefit from postoperative adjuvant chemotherapy without undergoing significant impairment of frailty, cognitive function, and quality of life. However, postoperative adjuvant chemotherapy might cause an aggravation of the frailty in patients who was already with it.Conclusion We should develop personalized treatment plans for elderly breast cancer patients after multidisciplinary assessment.

Citation： WU Yunhao, CHEN Jie. Impact of adjuvant chemotherapy on frailty, cognitive function, and quality of life in older patients with breast cancer. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2020, 27(9): 1175-1179. doi: 10.7507/1007-9424.202001071 Copy

1.	李贺, 郑荣寿, 张思维, 等. 2014 年中国女性乳腺癌发病与死亡分析. 中华肿瘤杂志, 2018, 40(3): 166-171.
2.	师金, 梁迪, 李道娟, 等. 全球女性乳腺癌流行情况研究. 中国肿瘤, 2017, 26(9): 683-690.
3.	马丹丹, 刘坤, 齐晓伟. 2018 年全球癌症统计: 乳腺癌发病和死亡人数统计. 中华乳腺病杂志: 电子版, 2018, 12(6): 375.
4.	Lyman GH, Dale DC, Crawford J. Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: a nationwide study of community practices. J Clin Oncol, 2003, 21(24): 4524-4531.
5.	高瑗, 原新. 中国老年人口健康转移与医疗支出. 人口研究, 2020, 44(2): 60-72.
6.	陈万青, 郑荣寿. 中国女性乳腺癌发病死亡和生存状况. 中国肿瘤临床, 2015, 42(13): 668-674.
7.	刘思业, 陈茂山, 杨光伦. 老年乳腺癌的特征及诊治研究进展. 中国普外基础与临床杂志, 2017, 24(4): 518-524.
8.	Muss HB, Woolf S, Berry D, et al. Adjuvant chemotherapy in older and younger women with lymph node-positive breast cancer. JAMA, 2005, 293(9): 1073-1081.
9.	Jung SP, Lee JE, Lee SK, et al. Adjuvant chemotherapy and survival of elderly korean patients with breast carcinoma. J Breast Cancer, 2012, 15(3): 296-305.
10.	Begg CB, Cohen JL, Ellerton J. Are the elderly predisposed to toxicity from cancer chemotherapy? An investigation using data from the Eastern Cooperative Oncology Group. Cancer Clin Trials, 1980, 3(4): 369-374.
11.	Dees EC, O’Reilly S, Goodman SN, et al. A prospective pharmacologic evaluation of age-related toxicity of adjuvant chemotherapy in women with breast cancer. Cancer Invest, 2000, 18(6): 521-529.
12.	Hamelinck VC, Bastiaannet E, Pieterse AH, et al. A prospective comparison of younger and older patients’ preferences for adjuvant chemotherapy and hormonal therapy in early breast cancer. Clin Breast Cancer, 2016, 16(5): 379-388.
13.	Singh R, Hellman S, Heimann R. The natural history of breast carcinoma in the elderly: implications for screening and treatment. Cancer, 2004, 100(9): 1807-1813.
14.	Fargeot P, Bonneterre J, Roché H, et al. Disease-free survival advantage of weekly epirubicin plus tamoxifen versus tamoxifen alone as adjuvant treatment of operable, node-positive, elderly breast cancer patients: 6-year follow-up results of the French adjuvant study group 08 trial. J Clin Oncol, 2004, 22(23): 4622-4630.
15.	Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet, 2005, 365(9472): 1687-1717.
16.	Inwald EC, Ortmann O, Koller M, et al. Screening-relevant age threshold of 70 years and older is a stronger determinant for the choice of adjuvant treatment in breast cancer patients than tumor biology. Breast Cancer Res Treat, 2017, 163(1): 119-130.
17.	Leinert E, Singer S, Janni W, et al. The impact of age on quality of life in breast cancer patients receiving adjuvant chemotherapy: a comparative analysis from the prospective multicenter randomized ADEBAR trial. Clin Breast Cancer, 2017, 17(2): 100-106.
18.	Mariano C, Lund JL, Peacock Hinton S, et al. Evaluating the association between adjuvant chemotherapy and function-related adverse events among older patients with early stage breast cancer. J Geriatr Oncol, 2017, 8(4): 242-248.
19.	Muss HB, Polley MC, Berry DA, et al. Randomized trial of standard adjuvant chemotherapy regimens versus capecitabine in older women with early breast cancer: 10-year update of the CALGB 49907 trial. J Clin Oncol, 2019, 37(26): 2338-2348.
20.	吕青, 陈洁. 对老年乳腺癌术后辅助化疗的再认识. 中国普外基础与临床杂志, 2013, 20(8): 833-837.
21.	Clegg A, Young J, Iliffe S, et al. Frailty in elderly people. Lancet, 2013, 381(9868): 752-762.
22.	Rockwood K, Fox RA, Stolee P, et al. Frailty in elderly people: an evolving concept. CMAJ, 1994, 150(4): 489-495.
23.	Mandelblatt JS, Cai L, Luta G, et al. Frailty and long-term mortality of older breast cancer patients: CALGB 369901 (Alliance). Breast Cancer Res Treat, 2017, 164(1): 107-117.
24.	Extermann M, Leeuwenburgh C, Samiian L, et al. Impact of chemotherapy on medium-term physical function and activity of older breast cancer survivors, and associated biomarkers. J Geriatr Oncol, 2017, 8(1): 69-75.
25.	Dalmasso B, Hatse S, Brouwers B, et al. Age-related microRNAs in older breast cancer patients: biomarker potential and evolution during adjuvant chemotherapy. BMC Cancer, 2018, 18(1): 1014.
26.	Bailur JK, Pawelec G, Hatse S, et al. Immune profiles of elderly breast cancer patients are altered by chemotherapy and relate to clinical frailty. Breast Cancer Res, 2017, 19(1): 20.
27.	Aaldriks AA, Giltay EJ, le Cessie S, et al. Prognostic value of geriatric assessment in older patients with advanced breast cancer receiving chemotherapy. Breast, 2013, 22(5): 753-760.
28.	中国痴呆与认知障碍指南写作组, 中国医师协会神经内科医师分会认知障碍疾病专业委员会. 2018 中国痴呆与认知障碍诊治指南(一): 痴呆及其分类诊断标准. 中华医学杂志, 2018, 98(13): 965-970.
29.	Leinert E, Schwentner L, Blettner M, et al. Association between cognitive impairment and guideline adherence for application of chemotherapy in older patients with breast cancer: results from the prospective multicenter BRENDA Ⅱ study. Breast J, 2019, 25(3): 386-392.
30.	Gregorowitsch ML, Ghedri A, Young-Afat DA, et al. The effect of chemotherapy on subjective cognitive function in younger early-stage breast cancer survivors treated with chemotherapy compared to older patients. Breast Cancer Res Treat, 2019, 175(2): 429-441.
31.	Chen BT, Sethi SK, Jin T, et al. Assessing brain volume changes in older women with breast cancer receiving adjuvant chemotherapy: a brain magnetic resonance imaging pilot study. Breast Cancer Res, 2018, 20(1): 38.
32.	Freedman RA, Pitcher B, Keating NL, et al. Cognitive function in older women with breast cancer treated with standard chemotherapy and capecitabine on Cancer and Leukemia Group B 49907. Breast Cancer Res Treat, 2013, 139(2): 607-616.
33.	邬沧萍. 提高对老年人生活质量的科学认识. 人口研究, 2002, 26(5): 1-5.
34.	Hurria A, Soto-Perez-de-Celis E, Allred JB, et al. Functional decline and resilience in older women receiving adjuvant chemotherapy for breast cancer. J Am Geriatr Soc, 2019, 67(5): 920-927.
35.	Brouwers B, Hatse S, Dal Lago L, et al. The impact of adjuvant chemotherapy in older breast cancer patients on clinical and biological aging parameters. Oncotarget, 2016, 7(21): 29977-29988.
36.	Quinten C, Kenis C, Hamaker M, et al. The effect of adjuvant chemotherapy on symptom burden and quality of life over time; a preliminary prospective observational study using individual data of patients aged ≥70 with early stage invasive breast cancer. J Geriatr Oncol, 2018, 9(2): 152-162.

1. 李贺, 郑荣寿, 张思维, 等. 2014 年中国女性乳腺癌发病与死亡分析. 中华肿瘤杂志, 2018, 40(3): 166-171.
2. 师金, 梁迪, 李道娟, 等. 全球女性乳腺癌流行情况研究. 中国肿瘤, 2017, 26(9): 683-690.
3. 马丹丹, 刘坤, 齐晓伟. 2018 年全球癌症统计: 乳腺癌发病和死亡人数统计. 中华乳腺病杂志: 电子版, 2018, 12(6): 375.
4. Lyman GH, Dale DC, Crawford J. Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: a nationwide study of community practices. J Clin Oncol, 2003, 21(24): 4524-4531.
5. 高瑗, 原新. 中国老年人口健康转移与医疗支出. 人口研究, 2020, 44(2): 60-72.
6. 陈万青, 郑荣寿. 中国女性乳腺癌发病死亡和生存状况. 中国肿瘤临床, 2015, 42(13): 668-674.
7. 刘思业, 陈茂山, 杨光伦. 老年乳腺癌的特征及诊治研究进展. 中国普外基础与临床杂志, 2017, 24(4): 518-524.
8. Muss HB, Woolf S, Berry D, et al. Adjuvant chemotherapy in older and younger women with lymph node-positive breast cancer. JAMA, 2005, 293(9): 1073-1081.
9. Jung SP, Lee JE, Lee SK, et al. Adjuvant chemotherapy and survival of elderly korean patients with breast carcinoma. J Breast Cancer, 2012, 15(3): 296-305.
10. Begg CB, Cohen JL, Ellerton J. Are the elderly predisposed to toxicity from cancer chemotherapy? An investigation using data from the Eastern Cooperative Oncology Group. Cancer Clin Trials, 1980, 3(4): 369-374.
11. Dees EC, O’Reilly S, Goodman SN, et al. A prospective pharmacologic evaluation of age-related toxicity of adjuvant chemotherapy in women with breast cancer. Cancer Invest, 2000, 18(6): 521-529.
12. Hamelinck VC, Bastiaannet E, Pieterse AH, et al. A prospective comparison of younger and older patients’ preferences for adjuvant chemotherapy and hormonal therapy in early breast cancer. Clin Breast Cancer, 2016, 16(5): 379-388.
13. Singh R, Hellman S, Heimann R. The natural history of breast carcinoma in the elderly: implications for screening and treatment. Cancer, 2004, 100(9): 1807-1813.
14. Fargeot P, Bonneterre J, Roché H, et al. Disease-free survival advantage of weekly epirubicin plus tamoxifen versus tamoxifen alone as adjuvant treatment of operable, node-positive, elderly breast cancer patients: 6-year follow-up results of the French adjuvant study group 08 trial. J Clin Oncol, 2004, 22(23): 4622-4630.
15. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet, 2005, 365(9472): 1687-1717.
16. Inwald EC, Ortmann O, Koller M, et al. Screening-relevant age threshold of 70 years and older is a stronger determinant for the choice of adjuvant treatment in breast cancer patients than tumor biology. Breast Cancer Res Treat, 2017, 163(1): 119-130.
17. Leinert E, Singer S, Janni W, et al. The impact of age on quality of life in breast cancer patients receiving adjuvant chemotherapy: a comparative analysis from the prospective multicenter randomized ADEBAR trial. Clin Breast Cancer, 2017, 17(2): 100-106.
18. Mariano C, Lund JL, Peacock Hinton S, et al. Evaluating the association between adjuvant chemotherapy and function-related adverse events among older patients with early stage breast cancer. J Geriatr Oncol, 2017, 8(4): 242-248.
19. Muss HB, Polley MC, Berry DA, et al. Randomized trial of standard adjuvant chemotherapy regimens versus capecitabine in older women with early breast cancer: 10-year update of the CALGB 49907 trial. J Clin Oncol, 2019, 37(26): 2338-2348.
20. 吕青, 陈洁. 对老年乳腺癌术后辅助化疗的再认识. 中国普外基础与临床杂志, 2013, 20(8): 833-837.
21. Clegg A, Young J, Iliffe S, et al. Frailty in elderly people. Lancet, 2013, 381(9868): 752-762.
22. Rockwood K, Fox RA, Stolee P, et al. Frailty in elderly people: an evolving concept. CMAJ, 1994, 150(4): 489-495.
23. Mandelblatt JS, Cai L, Luta G, et al. Frailty and long-term mortality of older breast cancer patients: CALGB 369901 (Alliance). Breast Cancer Res Treat, 2017, 164(1): 107-117.
24. Extermann M, Leeuwenburgh C, Samiian L, et al. Impact of chemotherapy on medium-term physical function and activity of older breast cancer survivors, and associated biomarkers. J Geriatr Oncol, 2017, 8(1): 69-75.
25. Dalmasso B, Hatse S, Brouwers B, et al. Age-related microRNAs in older breast cancer patients: biomarker potential and evolution during adjuvant chemotherapy. BMC Cancer, 2018, 18(1): 1014.
26. Bailur JK, Pawelec G, Hatse S, et al. Immune profiles of elderly breast cancer patients are altered by chemotherapy and relate to clinical frailty. Breast Cancer Res, 2017, 19(1): 20.
27. Aaldriks AA, Giltay EJ, le Cessie S, et al. Prognostic value of geriatric assessment in older patients with advanced breast cancer receiving chemotherapy. Breast, 2013, 22(5): 753-760.
28. 中国痴呆与认知障碍指南写作组, 中国医师协会神经内科医师分会认知障碍疾病专业委员会. 2018 中国痴呆与认知障碍诊治指南(一): 痴呆及其分类诊断标准. 中华医学杂志, 2018, 98(13): 965-970.
29. Leinert E, Schwentner L, Blettner M, et al. Association between cognitive impairment and guideline adherence for application of chemotherapy in older patients with breast cancer: results from the prospective multicenter BRENDA Ⅱ study. Breast J, 2019, 25(3): 386-392.
30. Gregorowitsch ML, Ghedri A, Young-Afat DA, et al. The effect of chemotherapy on subjective cognitive function in younger early-stage breast cancer survivors treated with chemotherapy compared to older patients. Breast Cancer Res Treat, 2019, 175(2): 429-441.
31. Chen BT, Sethi SK, Jin T, et al. Assessing brain volume changes in older women with breast cancer receiving adjuvant chemotherapy: a brain magnetic resonance imaging pilot study. Breast Cancer Res, 2018, 20(1): 38.
32. Freedman RA, Pitcher B, Keating NL, et al. Cognitive function in older women with breast cancer treated with standard chemotherapy and capecitabine on Cancer and Leukemia Group B 49907. Breast Cancer Res Treat, 2013, 139(2): 607-616.
33. 邬沧萍. 提高对老年人生活质量的科学认识. 人口研究, 2002, 26(5): 1-5.
34. Hurria A, Soto-Perez-de-Celis E, Allred JB, et al. Functional decline and resilience in older women receiving adjuvant chemotherapy for breast cancer. J Am Geriatr Soc, 2019, 67(5): 920-927.
35. Brouwers B, Hatse S, Dal Lago L, et al. The impact of adjuvant chemotherapy in older breast cancer patients on clinical and biological aging parameters. Oncotarget, 2016, 7(21): 29977-29988.
36. Quinten C, Kenis C, Hamaker M, et al. The effect of adjuvant chemotherapy on symptom burden and quality of life over time; a preliminary prospective observational study using individual data of patients aged ≥70 with early stage invasive breast cancer. J Geriatr Oncol, 2018, 9(2): 152-162.

Previous Article
Advances of serum exosome microRNAs in patients with colorectal cancer
Next Article
Research progress of long non-coding RNA CCAT1 and gastric cancer

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Impact of adjuvant chemotherapy on frailty, cognitive function, and quality of life in older patients with breast cancer

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content